Cargando…

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

BACKGROUND: Available data show that COVID-19 vaccines may be less effective in immunocompromised populations, who are at increased risk of severe COVID-19. OBJECTIVES: We conducted a systematic review of literature to assess immunogenicity, efficacy and effectiveness of COVID-19 vaccines in immunoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galmiche, Simon, Luong Nguyen, Liem Binh, Tartour, Eric, de Lamballerie, Xavier, Wittkop, Linda, Loubet, Paul, Launay, Odile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595936/ https://www.ncbi.nlm.nih.gov/pubmed/35020589 http://dx.doi.org/10.1016/j.cmi.2021.09.036

Ejemplares similares

COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
por: Kherabi, Yousra, et al.
Publicado: (2022)

2367. Six-month Humoral Response Following Two Or Three Doses Of Covid-19 Vaccines As Primary Vaccination Followed Or Not By a Booster Dose In Specific Populations – ANRS0001S COV-POPART Cohort Study
por: LOUBET, Paul, et al.
Publicado: (2023)

84. One-month Humoral Response Following Two Doses of Covid-19 Vaccines in Specific populations – ANRS0001S COV POPART Cohort Study
por: LOUBET, Paul, et al.
Publicado: (2022)

Re: ‘clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection’ by Mailhe et al.
por: Kherabi, Yousra, et al.
Publicado: (2023)

One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort
por: Loubet, Paul, et al.
Publicado: (2023)

Persistance à six mois des réponses immunitaires induites par une vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2 – cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2023)

Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study
por: Luong Nguyen, Liem Binh, et al.
Publicado: (2022)

What a second booster dose of mRNA COVID-19 vaccines tells us
por: Loubet, Paul, et al.
Publicado: (2022)

Influenza vaccination of pregnant women in Paris, France: Knowledge, attitudes and practices among midwives
por: Loubet, Paul, et al.
Publicado: (2019)

CO8.1 - Challenges inhérents à la mise en place d'une cohorte vaccinale COVID-19 pour les populations particulières en temps de crise: la cohorte ANRS0001S COV-POPART
por: Gilbert, C., et al.
Publicado: (2023)

Bonne réponse immunitaire humorale après vaccination contre le COVID-19 dans des populations particulières pédiatriques: cohorte observationnelle française
por: Toubiana, J., et al.
Publicado: (2023)

A national platform for Covid-19 vaccine studies recruitment in France: Covireivac volunteer’s characteristics
por: Bonneton, Marion, et al.
Publicado: (2022)

ANRS0001S COV-POPART : Réponse humorale des personnes vivant avec le VIH à 12 mois d'un schéma de vaccination Covid-19
por: Loubet, P., et al.
Publicado: (2023)

Cash interventions to improve clinical outcomes for pulmonary tuberculosis: systematic review and meta-analysis
por: Richterman, Aaron, et al.
Publicado: (2018)

Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort
por: Gaborit, Bénédicte, et al.
Publicado: (2023)

Patients’ Perception and Knowledge about Influenza and Pneumococcal Vaccination during the COVID-19 Pandemic: An Online Survey in Patients at Risk of Infections
por: Loubet, Paul, et al.
Publicado: (2021)

Immunité humorale à la vaccination Covid-19 en populations particulières : résultats préliminaires de la cohorte ANRS0001 S COV-POPART
por: Loubet, P., et al.
Publicado: (2022)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Efficacy of COVID-19 vaccines: From clinical trials to real life
por: Deplanque, Dominique, et al.
Publicado: (2021)

Suppression by Thimerosal of Ex-Vivo CD4(+) T Cell Response to Influenza Vaccine and Induction of Apoptosis in Primary Memory T Cells
por: Loison, Emily, et al.
Publicado: (2014)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

Modelling human-to-human transmission of monkeypox
por: Grant, Rebecca, et al.
Publicado: (2020)

1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study
por: Luong Nguyen, L.B., et al.
Publicado: (2022)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Silvestris, Nicola
Publicado: (2021)

Bartonella Infection in Immunocompromised Hosts: Immunology of Vascular Infection and Vasoproliferation
por: Mosepele, Mosepele, et al.
Publicado: (2012)

Vaccination of Immunocompromised Cats
por: Hartmann, Katrin, et al.
Publicado: (2022)

Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study
por: Dauriat, Gaëlle, et al.
Publicado: (2023)

Immunologic Response to SARS-CoV-2 Vaccination in Pediatric Kidney Transplant Recipients: A Systematic Review and Meta-Analysis
por: Emmanouilidou-Fotoulaki, Elpida, et al.
Publicado: (2023)

The Impact of High-Flow Nasal Cannula on the Outcome of Immunocompromised Patients with Acute Respiratory Failure: A Systematic Review and Meta-Analysis
por: Cheng, Li-Chin, et al.
Publicado: (2019)

HPV vaccination of immunocompromised hosts
por: Garland, S.M., et al.
Publicado: (2017)

Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systematic Review and Meta-Analysis
por: Chiu, Chia-Yu, et al.
Publicado: (2023)

Perception et connaissances des patients à haut risque d'infection sur la vaccination contre la grippe et le pneumocoque pendant la pandémie COVID-19
por: Loubet, P., et al.
Publicado: (2022)

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
por: Lee, Ainsley Ryan Yan Bin, et al.
Publicado: (2022)

Yellow fever vaccination for immunocompromised travellers: unjustified vaccination hesitancy?
por: de Jong, Wesley, et al.
Publicado: (2019)

Literature review on COVID-19 vaccine efficacy in the immunocompromised population, and possible implications to future vaccination in kidney transplant patients
por: Park, Joo Kyung, et al.
Publicado: (2023)

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years
por: Durier, Christine, et al.
Publicado: (2022)

Meta‐analysis: risk of hepatitis C virus infection associated with hospital‐based invasive procedures
por: Henriot, Paul, et al.
Publicado: (2022)

COVID-19 vaccination in immunocompromised patients
por: Sonani, Bhavin, et al.
Publicado: (2021)

Pneumococcal Vaccination in Immunocompromised Hosts: An Update
por: Froneman, Claire, et al.
Publicado: (2021)

Recurrent Bordetella holmesii Bacteremia and Nasal Carriage in a Patient Receiving Rituximab
por: Nguyen, Liem Binh Luong, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e100bmoc64s9ou11jhjbjqqgcm